Polyelectrolyte multilayers fabricated from antifungal β-peptides: design of surfaces that exhibit antifungal

Amy J Karlsson1, Ryan M Flessner, Samuel H Gellman

  • 1Department of Chemical and Biological Engineering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, Wisconsin 53706, USA.

Biomacromolecules
|September 14, 2010
PubMed

Insights

Researchers developed antifungal thin films to combat drug-resistant Candida albicans biofilms on medical devices. These β-peptide-releasing films significantly inhibited fungal growth and proliferation, offering a promising strategy for infection prevention.

Area of Science:

  • Biomaterials Science
  • Mycology
  • Infectious Diseases

Background:

  • Candida albicans forms drug-resistant biofilms on medical devices, leading to persistent infections.
  • Antifungal coatings are a potential strategy to prevent biofilm-associated infections.

Purpose of the Study:

  • To fabricate multilayered polyelectrolyte thin films (PEMs) for controlled release of an antifungal β-peptide.
  • To evaluate the efficacy of these β-peptide-releasing PEMs in inhibiting Candida albicans growth and biofilm formation.

Main Methods:

  • Layer-by-layer assembly of poly-l-glutamic acid (PGA) and poly-l-lysine (PLL) to create PEMs.
  • Incorporation of a fluorescently labeled antifungal β-peptide into the PEM structure.
  • Assessment of β-peptide release kinetics, film stability, and antifungal activity against C. albicans.

Main Results:

  • PEMs demonstrated stability at 37 °C and gradual β-peptide release for up to 400 hours.
  • β-peptide-containing films reduced C. albicans viability by 20% within 2 hours and metabolic activity by 74% within 7 hours.
  • Films inhibited C. albicans hyphal elongation by 55%.

Conclusions:

  • Fabricated β-peptide-containing thin films effectively inhibit Candida albicans growth and proliferation.
  • This approach provides a basis for developing medical device coatings to prevent C. albicans biofilm formation.
  • The layer-by-layer method offers a versatile strategy for coating medical devices to combat drug-resistant fungal infections in clinical settings.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...